Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors

Cross-talk between type I IGF receptor (IGF1R), insulin receptor (INSR), and epidermal growth factor receptor (EGFR) mediates resistance to individual receptor blockade. This study aimed to determine the MTD, safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of linsitini...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Clinical cancer research Ročník 22; číslo 12; s. 2897
Hlavní autori:	Macaulay, Valentine M, Middleton, Mark R, Eckhardt, S Gail, Rudin, Charles M, Juergens, Rosalyn A, Gedrich, Richard, Gogov, Sven, McCarthy, Sean, Poondru, Srinivasu, Stephens, Andrew W, Gadgeel, Shirish M
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 15.06.2016
Predmet:	Adult Aged Aged, 80 and over Antigens, CD Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Dose-Response Relationship, Drug Erlotinib Hydrochloride - adverse effects Erlotinib Hydrochloride - pharmacokinetics Erlotinib Hydrochloride - therapeutic use Female Humans Imidazoles - adverse effects Imidazoles - pharmacokinetics Imidazoles - therapeutic use Lung Neoplasms - drug therapy Male Maximum Tolerated Dose Middle Aged Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Pyrazines - adverse effects Pyrazines - pharmacokinetics Pyrazines - therapeutic use Receptor, Epidermal Growth Factor - antagonists & inhibitors Receptor, Insulin - antagonists & inhibitors Receptors, Somatomedin - antagonists & inhibitors Young Adult
ISSN:	1078-0432, 1557-3265, 1557-3265
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!